Delhi Delhi: A report on Tuesday stated that new research on GLP-1 receptor has opened a field of new treatment possibilities for the treatment of opioid use disorder (OUD). In a three -week phase I study held at the Caren Treatment Center in Pennsylvania in the US, 20 participants undergoing residential treatment for OUD were nominated, with Saxanda (Liraglutide) of Novo Nordisk as a monotherapy for OUD, one GLP-1 receptor agonist (GLP-1 RA) was evaluated.

According to a major data and analytics company Globaldeta, the study displayed its ability to compete with existing treatments and show a 40 percent decrease in the craving of opioids among those who take Saxnda. Originally developed to treat diabetes, GLP-1 RA works by stimulating insulin secretion and pressing the glucagon release, which helps regulate blood sugar.

“However, there are GLP-1 receptors in the brain's mesolimbic system, which are unwavering to inspire and reward. Globaldata's pharma analyst Jose Opdenkar said,” This has expanded the labels of its products to deal with the opioid crisis. The drugs that want have increased the interest of the developers. ”He said that initial clinical works have shown that The treatment of GLP-1ras OUD is a promising new path, as the current treatment landscape is suppressed by lack of innovation and heavy dependence on opioid agonist treatments.

According to GlobalData's drug database, six out of seven agents in the current phase development (Phase IIB-III) are non-opioides. Currently, there is a lack of efficacy data available for many pipeline agents. Therefore, despite the presence of non-opioids in the pipeline, high-efficiency non-opioid OD treatment remains an exploitative opportunity.

In addition to the OUD, GLP-1ras are also being examined in other neurology signals, such as Alzheimer's disease and cognitive loss, Parkinson's disease, alcohol dependence, peripheral neuropathy and intrachrinil hypertension. Developers have identified the ability of GLP-1ras, and a new class of neurological agents is developing.